Related Experiment Videos

Activation of the secretory pathway leads to a decrease in the intracellular amyloidogenic fragments generated from

D Fukushima1, M Konishi, K Maruyama

  • 1Minase Research Institute, Ono Pharmaceutical Co. Ltd., Osaka, Japan.

Biochemical and Biophysical Research Communications
|July 15, 1993
PubMed

Insights

Phorbol 12-myristate 13-acetate (PMA) treatment shifts amyloid precursor protein (APP) processing in glioblastoma cells. This metabolic switch reduces intracellular beta-amyloidogenic fragments by favoring secretion over lysosomal pathways.

Area of Science:

  • Neuroscience
  • Cell Biology
  • Biochemistry

Background:

  • Amyloid precursor protein (APP) processing is crucial in neurodegenerative diseases.
  • Glioblastoma cells exhibit altered APP metabolism.
  • The endosomal/lysosomal pathway is a key route for APP degradation.

Purpose of the Study:

  • To investigate the effect of phorbol 12-myristate 13-acetate (PMA) on APP processing in human glioblastoma cells.
  • To determine if PMA influences the intracellular levels of beta-amyloidogenic fragments.
  • To elucidate the pathway shift in APP metabolism induced by PMA.

Main Methods:

  • Treatment of human glioblastoma A-172 cells with PMA.
  • Analysis of intracellular beta-amyloidogenic fragments derived from APP.
  • Assessment of APP trafficking between endosomal/lysosomal and secretory pathways.

Main Results:

  • PMA treatment significantly decreased intracellular beta-amyloidogenic fragments in A-172 cells.
  • APP processing shifted from the endosomal/lysosomal pathway towards the secretory pathway.
  • This suggests a metabolic switch in APP handling following PMA stimulation.

Conclusions:

  • PMA activates the secretory pathway for APP, reducing harmful intracellular fragments.
  • The findings highlight a potential therapeutic strategy targeting APP metabolism in glioblastoma.
  • Glioblastoma A-172 cells demonstrate a modifiable APP processing pathway.

Related Concept Videos